Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Sybrava 284mg Injection
Manufacturer/Marketed By : NOVARTIS INDIA LTD
$1188.37 $962.58
Sybrava 284 mg Injection is a medicine containing Inclisiran as an active ingredient which belongs to the class of medications called proprotein convertase subtilisin kexin type-9 [PCSK-9]. It is first...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
INCLISIRAN
Active Pharmaceutical Ingredient
Sybrava 284mg Injection
$1,188.37
$962.58
Sybrava 284 mg Injection is a medicine containing Inclisiran as an active ingredient which belongs to the class of medications called proprotein convertase subtilisin kexin type-9 [PCSK-9]. It is first in class and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol. It is used to lower the level of low density lipoprotein. It is prescribed as a complement to statin medication and diet in the management of patients with primary high cholesterol levels. It is not recommended to use this medication if you are allergic to the active compound Sybrava Injection or its components. It is not recommended to use during pregnancy and breastfeeding; it is advised to consult your physician regarding further queries. It is not recommended for children and adolescents under the age of 18. You should be taking a statin and following a diet to reduce your cholesterol before beginning this therapy. For the duration that you are receiving Sybrava 284 mg, you should continue taking the statin and adhering to this cholesterol-lowering diet. Do not stop taking this medicine without consulting your doctor. Talk to your doctor if you have kidney disorders, breathing problems, liver disorders, heart problems, or intolerance to sugars before taking this medicine. Inform your physician or pharmacist of any additional medications you are taking, have recently taken, or may take, including over-the-counter medications and herbal remedies.
Active Pharmaceutical Ingredient
Uses
• Combination to other statin therapy and diet for treating primary hyperlipidemia [heterozygous familial hypercholesterolemia]
Benefits
Sybrava 284 mg Injection is a small interfering RNA (siRNA) molecule that interferes with the production of PCSK9 protein in the liver. By inhibiting PCSK9 synthesis, Sybrava 284 mg Injection increases the number of LDL receptors on liver cells, promoting the clearance of LDL cholesterol from the blood. This mechanism ultimately leads to lower LDL cholesterol levels in the bloodstream, helping to reduce the risk of cardiovascular events such as heart attack and stroke.
Side Effects
Like all medications, Sybrava 284 mg Injection can cause side effects, although not everyone who takes it will experience them. Sybrava injection side effects are:
Most Common Side Effects
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.
Common Side Effects
• Injection site reactions like redness, rash and pain
• Arthralgia
• Bronchitis
• Fever
• Chills
• Headache
How To Use
Sybrava 284 mg Injection will be administered to you by a healthcare professional in a hospital setting. It is usually administered as a subcutaneous injection into the abdomen, upper arm, or thigh. Your doctor will decide the dose, route of administration, and frequency based on your disease condition and other factors. The second dose is given after 3 months and the subsequent dose every 6 months.
Safety Advice
• Breast Feeding: It is unknown whether Sybrava 284mg Injection is excreted in human milk. It is advised to consult your doctor before taking Sybrava 284 mg Injection. Your doctor may prescribe this if the benefits of the drug outweighs the risks involved.
• Alcohol: It is unknown if consuming alcoholic beverages while taking Sybrava 284 mg Injection injection is safe. Please consult with your physician.
• Liver: Sybrava 284 mg Injection is primarily metabolized in the liver, so inform your healthcare provider if you have any liver problems or diseases.
• Lungs: It is unknown whether Sybrava 284 mg Injection Injection is safe for patients with lung problems. Consult your doctor if you have lung disease before starting the treatment.
• Driving: It is safe to travel, drive a car, or operate heavy machinery after receiving Sybrava 284mg Injection. The drug does not impair alertness or coordination.
• Pregnancy: It is recommended to avoid this medication during pregnancy as Sybrava 284 mg Injection is unsafe during pregnancy as it can cause fetal harm. It is advised to inform your physician if you are pregnant or think you may be pregnant before starting the treatment.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.